Literature DB >> 2622531

Quantitative autoradiography of the rat brain vesicular monoamine transporter using the binding of [3H]dihydrotetrabenazine and 7-amino-8-[125I]iodoketanserin.

F Darchen1, Y Masuo, M Vial, W Rostene, D Scherman.   

Abstract

The binding of [3H]dihydrotetrabenazine, a specific ligand of the monoamine transporter present on serotonin and catecholamine synaptic vesicles, was studied on rat brain sections. The characteristics of binding (Kd = 5.0 nM, k1 = 0.13 x 10(6) M-1 s-1; k-1 = 0.66 x 10(-3) s-1) were similar to those previously observed on tissue homogenates. The rostrocaudal topographical distribution of dihydrotetrabenazine binding sites was analysed by quantitative autoradiography. High labelling was observed in regions richly innervated by monoaminergic systems: dopamine in the striatum and olfactory tubercles, noradrenaline in the striatal fissure and in the paraventricular and dorsomedial hypothalamus and serotonin in the lateral septum, islands of Calleja and suprachiasmatic nucleus. Cell bodies were also labelled in the substantia nigra and ventral tegmental area (dopamine), in locus coeruleus (noradrenaline) and in raphe nucleus (serotonin). The pituitary gland (particularly the neural lobe) and the pineal gland were also labelled. Low labelling was observed in various areas of the cerebral cortex and in the cerebellum. Unilateral 6-hydroxydopamine lesion of the substantia nigra dramatically reduced [3H]dihydrotetrabenazine labelling in the ipsilateral striatum. Moreover, ketanserin has recently been shown to possess a nanomolar affinity for the vesicular monoamine transporter, and autoradiographic localization of brain monoaminergic synaptic vesicles was also obtained by means of the derivative 7-amino-8-[125I]iodoketanserin in the presence of 5-hydroxytryptamine2 and alpha 1 antagonists, although the non-specific labelling was higher than with [3H]dihydrotetrabenazine. It is concluded that [3H]dihydrotetrabenazine may represent a valuable monoaminergic marker in in vitro autoradiographic studies.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2622531     DOI: 10.1016/0306-4522(89)90214-5

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  9 in total

1.  Prolonged exposure of rats to intravenous methamphetamine: behavioral and neurochemical characterization.

Authors:  David S Segal; Ronald Kuczenski; Meghan L O'Neil; William P Melega; Arthur K Cho
Journal:  Psychopharmacology (Berl)       Date:  2005-03-15       Impact factor: 4.530

2.  Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography.

Authors:  Elissa M Strome; Ivan L Cepeda; Vesna Sossi; Doris J Doudet
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.488

3.  Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration.

Authors:  Goran Laćan; Martin Hadamitzky; Ronald Kuczenski; William P Melega
Journal:  Synapse       Date:  2013-03-19       Impact factor: 2.562

4.  The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat.

Authors:  J M Wilson; S J Kish
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

5.  Basal ganglia dopamine loss due to defect in purine recycling.

Authors:  Kiyoshi Egami; Silaja Yitta; Suhail Kasim; J Chris Lewers; Rosalinda C Roberts; Mohamed Lehar; H A Jinnah
Journal:  Neurobiol Dis       Date:  2007-02-08       Impact factor: 5.996

6.  Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.

Authors:  Lisa M McFadden; Amanda J Hoonakker; Paula L Vieira-Brock; Kristen A Stout; Nicole M Sawada; Jonathan D Ellis; Scott C Allen; Elliot T Walters; Shannon M Nielsen; James W Gibb; Mario E Alburges; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  Synapse       Date:  2011-03-21       Impact factor: 2.562

Review 7.  Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Authors:  Kandatege Wimalasena
Journal:  Med Res Rev       Date:  2010-02-04       Impact factor: 12.944

8.  Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies.

Authors:  Junchao Tong; Isabelle Boileau; Yoshiaki Furukawa; Li-Jan Chang; Alan A Wilson; Sylvain Houle; Stephen J Kish
Journal:  J Cereb Blood Flow Metab       Date:  2011-04-27       Impact factor: 6.200

9.  Comparison of the subregional distributions of the monoamine vesicular transporter and dopamine uptake complex in the rat striatum and changes during aging.

Authors:  I Leroux-Nicollet; J Costentin
Journal:  J Neural Transm Gen Sect       Date:  1994
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.